AV Therapeutics, Inc.

CIK:0001537293|SEC Filings

NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS (Details) (USD $)			0 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Jan. 08, 2014 Advanced Vaccine Therapeutics, Inc. [Member]	Dec. 13, 2013 Advanced Vaccine Therapeutics, Inc. [Member]	Dec. 31, 2013 Advanced Vaccine Therapeutics, Inc. [Member]	Dec. 13, 2013 Advanced Vaccine Therapeutics, Inc. [Member]
NOTE 1. ORGANIZATION AND NATURE OF OPERATIONS (Details) [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares				58,000,000
Stock Repurchased and Retired During Period, Shares				70,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt (in Dollars)						$ 7,320
Debt Instrument, Convertible, Conversion Price (in Dollars per share)					$ 0.20
Common Stock, Value, Subscriptions (in Dollars)	$ 0	$ 1,056,159			$ 7,320
Stock Issued During Period, Shares, Conversion of Convertible Securities			36,596

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:
Net loss	$ (330,210)	$ (459,975)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	15,132	15,131
Depreciation	324	324
Stock-based compensation	281,603	0
Unrealized gain on change in fair value of derivative liabilities	(888,771)	0
Changes in operating assets and liabilities:
Prepaid expenses	39,250	0
Accounts payable and accrued expenses	58,643	197,145
Net cash used in operating activities	(824,029)	(247,375)
Cash flows from financing activities:
Proceeds received from issuance of common stock, net of issuance costs	525,000	225,000
Proceeds received from note payable - related parties	(4,000)	0
Net cash provided by financing activities	521,000	225,000
Net (decrease) increase in cash	(303,029)	(22,375)
Cash at beginning of period	576,251	97,436
Cash at end of period	273,222	75,061
Supplemental disclosures:
Cash paid for interest	0	0
Cash paid for taxes	0	0
Non-cash investing and financing activities:
Recognition of derivative liability - warrants	1,080,893	0
Stock Issued for Accrued Executive Compensation [Member]
Non-cash investing and financing activities:
Issuance of common stock	72,000	0
Stock Issued for Accrued Consulting Fees [Member]
Non-cash investing and financing activities:
Issuance of common stock	$ 27,500	$ 0

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current assets:
Cash	$ 273,222	$ 576,251
Prepaid expenses	20,750	60,000
Total current assets	293,972	636,251
Property and equipment, net of accumulated depreciation of $1,403 and $1,079, respectively	755	1,079
Intangible assets, net of accumulated amortization of $97,535 and $82,403, respectively	132,465	147,597
Total assets	427,192	784,927
Current liabilities:
Accounts payable and accrued expenses	465,193	452,050
Derivative liability - warrants	192,122	0
Notes payable	97,000	97,000
Notes payable - related parties	197,705	201,705
Total current liabilities	952,020	750,755
Commitments and Contingencies
Stockholders' (deficiency) equity:
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; none issued and outstanding	0	0
Common stock, $0.0001 par value: 250,000,000 shares authorized; 81,880,963 and 72,000,000 shares issued and outstanding, respectively	8,188	7,200
Additional paid in capital	4,534,061	3,707,680
Shares Issuable	0	1,056,159
Accumulated deficit	(5,067,077)	(4,736,867)
Total stockholders' (deficiency) equity	(524,828)	34,172
Total liabilities and stockholders' (deficiency) equity	$ 427,192	$ 784,927